Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset

Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used...

Descripción completa

Detalles Bibliográficos
Autores principales: Pobiruchin, Monika, Bochum, Sylvia, Martens, Uwe M., Kieser, Meinhard, Schramm, Wendelin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802671/
https://www.ncbi.nlm.nih.gov/pubmed/27054173
http://dx.doi.org/10.1016/j.dib.2016.03.039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802671/
https://www.ncbi.nlm.nih.gov/pubmed/27054173
http://dx.doi.org/10.1016/j.dib.2016.03.039

Ejemplares similares